PubMed:8810619
Annnotations
Inflammaging
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 0-116 | Sentence | denotes | Tyloxapol inhibits NF-kappa B and cytokine release, scavenges HOCI, and reduces viscosity of cystic fibrosis sputum. |
| T2 | 117-364 | Sentence | denotes | Cystic fibrosis (CF) patients develop progressive cytokine-mediated inflammatory lung disease, with abundant production of thick, tenacious, protease- and oxidant-rich purulent airway secretions that are difficult to clear even with physiotherapy. |
| T3 | 365-546 | Sentence | denotes | In the search for a potential treatment, we have tested tyloxapol, an alkylaryl polyether alcohol polymer detergent previously used as a mucolytic agent in adult chronic bronchitis. |
| T4 | 547-979 | Sentence | denotes | Tyloxapol inhibits activation of the transcription factor nuclear factor-kappa B (NK-kappa B), reduces resting secretion of the cytokine interleukin-8 (IL-8) in cultured human monocytes, and inhibits lipopolysaccharide (LPS)-stimulated release of tumor necrosis factor-alpha (TNF-alpha), IL-1 beta, IL-6, IL-8, granulocyte-macrophage colony-stimulating factor (GM-CSF), and the eiconsanoids thromboxane A2 and leukotriene B4 (LTB4). |
| T5 | 980-1072 | Sentence | denotes | We have previously shown that tyloxapol is a potent antioxidant for hydroxyl radicals ( OH). |
| T6 | 1073-1239 | Sentence | denotes | Tyloxapol (0.05 to 0.1% wt/vol) effectively scavenges the oxidant hypochlorous acid (HOCl; 1 to 7.5 mM) in vitro, and protects from HOCl-mediated lung injury in rats. |
| T7 | 1240-1334 | Sentence | denotes | Tyloxapol also reduces the viscosity of CF sputum (from 463 +/- 133 to 128 +/- 52 centipoise). |
| T8 | 1335-1507 | Sentence | denotes | We conclude that tyloxapol is potentially useful as a new antiinflammatory therapy for CF lung disease, and could possibly promote clearance of secretions in the CF airway. |
| T1 | 0-116 | Sentence | denotes | Tyloxapol inhibits NF-kappa B and cytokine release, scavenges HOCI, and reduces viscosity of cystic fibrosis sputum. |
| T2 | 117-364 | Sentence | denotes | Cystic fibrosis (CF) patients develop progressive cytokine-mediated inflammatory lung disease, with abundant production of thick, tenacious, protease- and oxidant-rich purulent airway secretions that are difficult to clear even with physiotherapy. |
| T3 | 365-546 | Sentence | denotes | In the search for a potential treatment, we have tested tyloxapol, an alkylaryl polyether alcohol polymer detergent previously used as a mucolytic agent in adult chronic bronchitis. |
| T4 | 547-979 | Sentence | denotes | Tyloxapol inhibits activation of the transcription factor nuclear factor-kappa B (NK-kappa B), reduces resting secretion of the cytokine interleukin-8 (IL-8) in cultured human monocytes, and inhibits lipopolysaccharide (LPS)-stimulated release of tumor necrosis factor-alpha (TNF-alpha), IL-1 beta, IL-6, IL-8, granulocyte-macrophage colony-stimulating factor (GM-CSF), and the eiconsanoids thromboxane A2 and leukotriene B4 (LTB4). |
| T5 | 980-1072 | Sentence | denotes | We have previously shown that tyloxapol is a potent antioxidant for hydroxyl radicals ( OH). |
| T6 | 1073-1239 | Sentence | denotes | Tyloxapol (0.05 to 0.1% wt/vol) effectively scavenges the oxidant hypochlorous acid (HOCl; 1 to 7.5 mM) in vitro, and protects from HOCl-mediated lung injury in rats. |
| T7 | 1240-1334 | Sentence | denotes | Tyloxapol also reduces the viscosity of CF sputum (from 463 +/- 133 to 128 +/- 52 centipoise). |
| T8 | 1335-1507 | Sentence | denotes | We conclude that tyloxapol is potentially useful as a new antiinflammatory therapy for CF lung disease, and could possibly promote clearance of secretions in the CF airway. |
jnlpba-st-training
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 19-29 | protein | denotes | NF-kappa B |
| T2 | 34-42 | protein | denotes | cytokine |
| T3 | 62-66 | protein | denotes | HOCI |
| T4 | 167-175 | protein | denotes | cytokine |
| T5 | 258-266 | protein | denotes | protease |
| T6 | 584-627 | protein | denotes | transcription factor nuclear factor-kappa B |
| T7 | 629-639 | protein | denotes | NK-kappa B |
| T8 | 675-683 | protein | denotes | cytokine |
| T9 | 684-697 | protein | denotes | interleukin-8 |
| T10 | 699-703 | protein | denotes | IL-8 |
| T11 | 708-732 | cell_line | denotes | cultured human monocytes |
| T12 | 794-821 | protein | denotes | tumor necrosis factor-alpha |
| T13 | 823-832 | protein | denotes | TNF-alpha |
| T14 | 835-844 | protein | denotes | IL-1 beta |
| T15 | 846-850 | protein | denotes | IL-6 |
| T16 | 852-856 | protein | denotes | IL-8 |
| T17 | 858-906 | protein | denotes | granulocyte-macrophage colony-stimulating factor |
| T18 | 908-914 | protein | denotes | GM-CSF |
genia-medco-coref
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| C1 | 0-9 | NP | denotes | Tyloxapol |
| C2 | 217-311 | NP | denotes | abundant production of thick, tenacious, protease- and oxidant-rich purulent airway secretions |
| C3 | 312-316 | NP | denotes | that |
| C4 | 421-430 | NP | denotes | tyloxapol |
| C5 | 432-545 | NP | denotes | an alkylaryl polyether alcohol polymer detergent previously used as a mucolytic agent in adult chronic bronchitis |
| C6 | 547-556 | NP | denotes | Tyloxapol |
| C7 | 671-704 | NP | denotes | the cytokine interleukin-8 (IL-8) |
| C8 | 852-856 | NP | denotes | IL-8 |
| C9 | 1010-1019 | NP | denotes | tyloxapol |
| C10 | 1073-1082 | NP | denotes | Tyloxapol |
| C11 | 1240-1249 | NP | denotes | Tyloxapol |
| C12 | 1352-1361 | NP | denotes | tyloxapol |
| R1 | C3 | C2 | coref-relat | that,"abundant production of thick, tenacious, protease- and oxidant-rich purulent airway secretions" |
| R2 | C4 | C1 | coref-ident | tyloxapol,Tyloxapol |
| R3 | C5 | C4 | coref-appos | an alkylaryl polyether alcohol polymer detergent previously used as a mucolytic agent in adult chronic bronchitis,tyloxapol |
| R4 | C6 | C4 | coref-ident | Tyloxapol,tyloxapol |
| R5 | C8 | C7 | coref-ident | IL-8,the cytokine interleukin-8 (IL-8) |
| R6 | C9 | C6 | coref-ident | tyloxapol,Tyloxapol |
| R7 | C10 | C9 | coref-ident | Tyloxapol,tyloxapol |
| R8 | C11 | C10 | coref-ident | Tyloxapol,Tyloxapol |
| R9 | C12 | C11 | coref-ident | tyloxapol,Tyloxapol |
pubmed-sentences-benchmark
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| S1 | 0-116 | Sentence | denotes | Tyloxapol inhibits NF-kappa B and cytokine release, scavenges HOCI, and reduces viscosity of cystic fibrosis sputum. |
| S2 | 117-364 | Sentence | denotes | Cystic fibrosis (CF) patients develop progressive cytokine-mediated inflammatory lung disease, with abundant production of thick, tenacious, protease- and oxidant-rich purulent airway secretions that are difficult to clear even with physiotherapy. |
| S3 | 365-546 | Sentence | denotes | In the search for a potential treatment, we have tested tyloxapol, an alkylaryl polyether alcohol polymer detergent previously used as a mucolytic agent in adult chronic bronchitis. |
| S4 | 547-979 | Sentence | denotes | Tyloxapol inhibits activation of the transcription factor nuclear factor-kappa B (NK-kappa B), reduces resting secretion of the cytokine interleukin-8 (IL-8) in cultured human monocytes, and inhibits lipopolysaccharide (LPS)-stimulated release of tumor necrosis factor-alpha (TNF-alpha), IL-1 beta, IL-6, IL-8, granulocyte-macrophage colony-stimulating factor (GM-CSF), and the eiconsanoids thromboxane A2 and leukotriene B4 (LTB4). |
| S5 | 980-1072 | Sentence | denotes | We have previously shown that tyloxapol is a potent antioxidant for hydroxyl radicals ( OH). |
| S6 | 1073-1239 | Sentence | denotes | Tyloxapol (0.05 to 0.1% wt/vol) effectively scavenges the oxidant hypochlorous acid (HOCl; 1 to 7.5 mM) in vitro, and protects from HOCl-mediated lung injury in rats. |
| S7 | 1240-1334 | Sentence | denotes | Tyloxapol also reduces the viscosity of CF sputum (from 463 +/- 133 to 128 +/- 52 centipoise). |
| S8 | 1335-1507 | Sentence | denotes | We conclude that tyloxapol is potentially useful as a new antiinflammatory therapy for CF lung disease, and could possibly promote clearance of secretions in the CF airway. |
GENIAcorpus
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 0-9 | other_organic_compound | denotes | Tyloxapol |
| T2 | 19-29 | protein_complex | denotes | NF-kappa B |
| T3 | 34-42 | protein_family_or_group | denotes | cytokine |
| T4 | 62-66 | protein_molecule | denotes | HOCI |
| T5 | 93-115 | other_name | denotes | cystic fibrosis sputum |
| T6 | 117-146 | multi_cell | denotes | Cystic fibrosis (CF) patients |
| T7 | 167-175 | protein_family_or_group | denotes | cytokine |
| T8 | 258-266 | protein_family_or_group | denotes | protease |
| T9 | 350-363 | other_name | denotes | physiotherapy |
| T10 | 421-430 | other_organic_compound | denotes | tyloxapol |
| T11 | 435-480 | other_organic_compound | denotes | alkylaryl polyether alcohol polymer detergent |
| T12 | 502-517 | other_organic_compound | denotes | mucolytic agent |
| T13 | 521-545 | other_name | denotes | adult chronic bronchitis |
| T14 | 547-556 | other_organic_compound | denotes | Tyloxapol |
| T15 | 584-627 | protein_complex | denotes | transcription factor nuclear factor-kappa B |
| T16 | 629-639 | protein_complex | denotes | NK-kappa B |
| T17 | 675-683 | protein_family_or_group | denotes | cytokine |
| T18 | 684-697 | protein_molecule | denotes | interleukin-8 |
| T19 | 699-703 | protein_molecule | denotes | IL-8 |
| T20 | 708-732 | cell_line | denotes | cultured human monocytes |
| T21 | 747-765 | lipid | denotes | lipopolysaccharide |
| T22 | 767-770 | lipid | denotes | LPS |
| T23 | 794-821 | protein_molecule | denotes | tumor necrosis factor-alpha |
| T24 | 823-832 | protein_molecule | denotes | TNF-alpha |
| T25 | 835-844 | protein_molecule | denotes | IL-1 beta |
| T26 | 846-850 | protein_molecule | denotes | IL-6 |
| T27 | 852-856 | protein_molecule | denotes | IL-8 |
| T28 | 858-906 | protein_molecule | denotes | granulocyte-macrophage colony-stimulating factor |
| T29 | 908-914 | protein_molecule | denotes | GM-CSF |
| T30 | 925-937 | other_organic_compound | denotes | eiconsanoids |
| T31 | 938-952 | other_organic_compound | denotes | thromboxane A2 |
| T32 | 957-971 | other_organic_compound | denotes | leukotriene B4 |
| T33 | 973-977 | other_organic_compound | denotes | LTB4 |
| T34 | 1010-1019 | other_organic_compound | denotes | tyloxapol |
| T35 | 1032-1043 | other_name | denotes | antioxidant |
| T36 | 1048-1065 | inorganic | denotes | hydroxyl radicals |
| T37 | 1068-1070 | inorganic | denotes | OH |
| T38 | 1073-1082 | other_organic_compound | denotes | Tyloxapol |
| T39 | 1139-1156 | inorganic | denotes | hypochlorous acid |
| T40 | 1158-1162 | inorganic | denotes | HOCl |
| T41 | 1205-1209 | inorganic | denotes | HOCl |
| T42 | 1240-1249 | other_organic_compound | denotes | Tyloxapol |
| T43 | 1280-1289 | other_name | denotes | CF sputum |
| T44 | 1352-1361 | other_organic_compound | denotes | tyloxapol |
| T45 | 1393-1417 | other_name | denotes | antiinflammatory therapy |
| T46 | 1422-1437 | other_name | denotes | CF lung disease |
| T47 | 1479-1489 | other_name | denotes | secretions |
| T48 | 1497-1506 | other_name | denotes | CF airway |